FHA
RNAM

First Horizon Advisors’s Avidity Biosciences RNAM Stock Holding History

First Horizon Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$13.9K Sell
490
-72
-13% -$2.15K ﹤0.01% 1554
2025
Q1 		$16.6K Buy
562
+288
+105% +$8.97K ﹤0.01% 1405
2024
Q4 		$7.97K Hold
274
– – ﹤0.01% 1678
2024
Q3 		$12.6K Buy
+274
New +$11.9K ﹤0.01% 1535

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's RNAM Position: Q2 2025 in Review

First Horizon Advisors reduced its Avidity Biosciences (RNAM) stake by 13% in Q2 2025, selling an estimated $2.15K and leaving 490 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

First Horizon Advisors first reported a position in RNAM in Q3 2024 and has held it in 4 quarters since. The position peaked at $16.6K in Q1 2025. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • First Horizon Advisors held 490 shares of Avidity Biosciences worth $13.9K as of Q2 2025.
  • First Horizon Advisors sold 72 Avidity Biosciences shares in Q2 2025, an estimated $2.15K.
  • Avidity Biosciences made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1554 holding.
  • First Horizon Advisors first reported a position in Avidity Biosciences in Q3 2024 and has held it in 4 quarters since.
  • First Horizon Advisors's Avidity Biosciences position peaked at $16.6K in Q1 2025.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.